New Data from Phase 2 Study Evaluating KEYTRUDA ® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced updated findings from a study evaluating KEYTRUDA < sup > ® < /sup >
(pembrolizumab), the company ’s anti-PD-1 therapy, in patients with
advanced cancers characterized as deficient for DNA mismatch repair
(MMR). < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div class= " field-item odd " >
English < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-contact-html field-fieldpressreleasecontacthtml " > < div class= " field-label " > Contact: < /div > < div class= " field-items " > < div class= " field-item odd " > < p > Merck < br / > Media: < br / > Pamela Eisele, 267-305-3558 < br / > Kim Hamilton, 908-740-1863 < br / > or < br / > Investors: < br / > Teri Loxam, 908-740-1986 < br / > Justin Holko, 908-740-1879 < /p > < p > < /p > < /div > ...
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK ASCO Keytruda MSD Source Type: news